Shares of Ra Pharma were exploding on Thursday after it was announced that the company would be acquired by Belgium-based UCB for $2.1 billion. The transaction would immediately double the market value of the Cambridged-based biotech which is in late stage trials of a drug called zilucoplan that treats a rare muscle disease called generalized … Continue reading “Ra Pharmaceuticals Inc. is Acquired for $2.1 Billion”
